StimCell Energetics https://validator.w3.org/feed/docs/rss2.html Our Goal StimCell Energetics Engages Stonegate Capital Markets as Non-Exclusive Advisor for Strategic Capital Market Transactions Contact us StimCell Energetics Engages Stonegate Capital Partners for Research Coverage and Institutional Investor Outreach Cell MedX Corp. Announces Signing of Definitive Agreement to Acquire Technology for Treating Diabetes and Related Ailments CELL MEDX CORP. Announces Full Revocation of British Columbia Cease Trade Order Cell MedX Corp. Appoints Audit Committee and Accepts Resignation of Chief Operating Officer Cell MedX Amends Loan Agreements, Provides Update on Financing and Regulatory Compliance FDA Submission and Corporate Update Cell MedX Corp. Provides Letter to Shareholders from Mr. Dwayne Yaretz, CEO Cell MedX Corp. Appoints Mr. Dwayne Yaretz as CEO and Director Cell MedX Corp. to Attend The 29th Annual Wellness Show 2022 Held in Vancouver, BC FDA Commences Review of Cell MedX’s Premarket Notification (510K) and Health Canada Renews Class II Medical Device Licenses for eBalance(R) Systems StimCell Energetics Inc. Signs Marketing Agreement with Think Ink Marketing SEC Filings Cell MedX Corp. Converts Debt to Shares, Closes Non-brokered Private Placement Financing, and Engages Investor Relations Consultants Cell MedX Corp. Signs Extension Agreement with Think Ink Marketing Cell MedX Corp.’s eBalance Pro System Receives Class II Medical Device License from Health Canada Cell MedX Corp. (CMXC) Closes Non-Brokered Private Placement Financing Cell MedX Corp.’s eBalance Home System Receives Class II Medical Device License from Health Canada Cell MedX Corp. Files Two Applications for Class II Medical Device Licenses with Health Canada Cell MedX Corp. Receives Quality Management System ISO 13485:2016 MDSAP Certificate Cell MedX Corp. Announces a Non-Brokered Private Placement Financing Cell MedX Corp. Receives Quality Management System ISO 13485:2016 Certificate for the eBalance® Device Cell MedX Corp. Reacquires World Wide Exclusivity Rights for the eBalanceⓇ Device Cell MedX Corp. Engages Dr. Peter Eppinga as Lead Investigator in the eBalance R&D Experience Study Trial Results StimCell Energetics Partners with ADM Tronics to Redesign eBalance® Microcurrent Device for Home Use StimCell Energetics Inc. Announces Study into eBalance® Device’s Impact on Neuronal Mitochondrial Function CELL MEDX CORP. ISSUES CLARIFYING RELEASE REGARDING THE BULL REPORT ARTICLE Cell MedX Corp. (CMXC) Receives Approval to Commence Family Practice (BC) Observational Study Cell MedX Corp. (CMXC) Closes the First Tranche of its Non-brokered Private Placement Financing Cell MedX Corp. (CMXC) Engages Think Ink Marketing Cell MedX Corp. (CMXC) Arranges a Non-brokered Private Placement Financing Cell MedX signs Definitive Worldwide Distribution Rights Agreement with Live Current Media, Inc. Cell MedX Corp. Files Premarket Notification (510K) with the US Food and Drug Administration and Receives Canadian Trademark StimCell Energetics Provides Sneak Peek at eBalance Redesign Progress and Announces Shares for Debt Transaction and the engagement of Independent Investor Relations Consultant StimCell Energetics Inc. Successfully Uplists to OTCQB Market eBalance StimCell Energetics Inc. Launches Social Media Presence Footer Tax Solutions Bio Feedback Cell MedX Corp. Receives eBalance Trademark Stock Quote StimCell Energetics Inc. (formerly “Cell MedX Corp.”) Announces Major Corporate Updates and Rebranding 3 Small-Cap Biotech Stocks That Are Challenging the Status Quo Cell MedX Corp. Provides Corporate Update Cell MedX Aiming to Change Diabetes Care Forever Watch a Q&A video with CMXC CEO Frank McEnulty and Chief Medical Officer John Sanderson, MD StimCell